California Schedule II Prescription Refill Rules
In California, Schedule II controlled substances (including stimulant medications) cannot have refills written on the prescription—each new supply requires a completely new prescription. However, practitioners can write multiple prescriptions at once for up to a 90-day supply under specific conditions.
Key Regulatory Framework
No Refills Allowed
Schedule II medications, due to their controlled substance classification, do not permit refills on a single prescription 1. This is a federal DEA requirement that California follows strictly.
Practical Prescribing Options
Monthly prescriptions are the standard approach:
- Practitioners can write prescriptions on a monthly basis for ongoing treatment 1
- Each month requires a new prescription to be written and signed
90-day supply option (similar to New York State's model):
- Clinicians can write prescriptions "sometimes once every 3 months" 1
- This involves writing three separate prescriptions at the same visit, each dated for sequential 30-day periods
- The patient receives all three prescriptions but can only fill them on or after their respective dates
- This reduces visit frequency while maintaining Schedule II controls
Clinical Visit Requirements
For stable patients:
- Children with stable responses and no comorbidities can be seen once every 3-4 months 1
- Monthly visits are not mandatory if the patient is doing well
For complex cases:
- Patients with complex comorbidity or significant side effects may require monthly visits 1
Important Caveat
While prescriptions can be written for 90-day intervals using multiple prescriptions, the actual clinical monitoring schedule should be based on patient stability, not just prescription convenience. The evidence shows that monthly 30-minute medication visits with assessment of symptoms and side effects produce superior outcomes compared to less frequent monitoring 1.
California-Specific Context
California has historically maintained strict controls on Schedule II substances, including a triplicate prescription system for Schedule II narcotics 2. While the specific triplicate system has evolved, the state continues to emphasize careful oversight of these medications to prevent diversion while ensuring legitimate medical access.